1. Introduction {#sec0005}
===============

Liver injury is a major public health problem all over the world and it affects approximately 30% of the US population ([@bib0165]). More than 900 drugs have been implicated in inducing liver injury as an adverse effect, a predominantly compelling reason for drug withdrawal from the market ([@bib0065]). Valproate (VPA) is a widely used drug for treatment of epileptic seizures, bipolar and schizoaffective disorders, trigeminal neuralgia, social phobias, migraine pain and neuropathic pain ([@bib0100]). However, VPA has major adverse reactions, including gastrointestinal disorders ([@bib0085]), hemorrhagic pancreatitis, bone-marrow suppression and a more frequently hepatic injury ([@bib0070]). Hyperammonemia has been reported in patients using VPA therapy ([@bib0190]). With chronic use of VPA, 44% of patients showed elevated serum liver enzymes and lipid peroxidation. Moreover, VPA therapy is associated with the development of fatty liver ([@bib0235]) that can progress to hepatic necrosis, apoptosis. While most of these reactions are VPA-dose- and time-dependent, some serious ones are not so, as they involve type-2 unpredictable (idiosyncratic) fatal reactions ([@bib0170]).

VPA is extensively metabolized in the liver *via* glucuronic acid conjugation, mitochondrial β-oxidation and cytosolic ω-oxidation to produce multiple metabolites; some of them are biologically active and could mediate VPA-induced hepatotoxicity. For instance, 4-ene-valproic (4-ene-VPA) is a more potent hepatotoxic than VPA and can trigger oxidative cascades that deplete reduced-glutathione, an indispensable antioxidant cellular protector ([@bib0095]). Moreover, valproate-induced activation of CYP2E1 and subsequently oxidative stress may provoke serious proteolytic reactions in hepatocytes, thereby damaging liver cell membranes and leaking out intracellular enzymes ([@bib0095]).

Docosahexaenoic acid/DHA is a biologically active polyunsaturated omega-3 fatty acid (ω-3 FA). DHA is found mainly in fish oil and the metabolic products of a third plant-derived ω-3 FA, alpha-linolenic acid ([@bib0105]). DHA has numerous health benefits as it regulates membrane bound enzymes (Na^+^/K^+^-dependent ATPase) and plays a role in signal transduction by modulating inositol phosphates, diacylglycerol (DAG), and protein kinase C pathways ([@bib0010]). Moreover, DHA directly influences biosynthesis, signaling and uptake of serotonin, a CNS crucial neurotransmitter ([@bib0155]). DHA also affects cell membrane structure and function ([@bib0210]) and plays an important role in controlling malignant, inflammatory, proliferative and vascular diseases ([@bib0180]). Interestingly, this n-3FA is an approved OTC supplement/drug for both children and adults, thereby displaying a wide safety margin and high therapeutic index ([@bib0050]; [@bib0155]).

We have previously demonstrated the efficacy of DHA, or its analog (EPA) against VPA-induced hepatotoxicity, and doxorubicin-evoked renal injury ([@bib0045]; [@bib0050]). Therefore, the current study was undertaken to extend our previous findings by investigating the molecular basis and mechanistic pathways whereby VPA evokes, while DHA may abate, hepatotoxicity. The impact and contribution of novel cellular components in VPA-induced hepatotoxicity that could exacerbate oxidative stress, hypoxia, inflammation and apoptosis were evaluated, then further challenged by co-administration of DHA.

2. Materials and methods {#sec0010}
========================

2.1. Drugs and chemicals {#sec0015}
------------------------

Sodium valproate was obtained from Cayman Chemical Company, USA, and was dissolved in distilled water. DHA was purchased from Swanson Health Product, North Dakota, USA, as capsules; each provides 250 mg of pure DHA. DHA was diluted in corn oil, with equivalent amounts of oil given to all animals in the control group.

2.2. Animal studies {#sec0020}
-------------------

All procedures with animals were performed in accordance with the Public Health Service Guide for the Care and Use of Laboratory Animals and Augusta University guidelines, and approved by the Institutional Animal Care and Use Committee of Augusta University. Twelve week old male Sprague Dawley rats were purchased from Harlan Laboratory and used in the current study. Three group of rats were used in our study (n = 6--8 rats/group) as follows; *Control-group* received vehicle (corn oil daily) for 2 weeks, *VPA-group* received VPA alone (500 mg/kg PO, daily) for two weeks, *VPA + DHA-group* received VPA (500 mg/kg PO, daily), followed by DHA (250 mg/kg PO, daily) for two weeks. After two weeks of treatment, rats were terminated using sodium pentobarbital (50 mg/kg, IP) for liver collection. Liver was isolated, weighed, aliquoted in few tubes and snap frozen in liquid nitrogen. A 10% (w/v) liver homogenate was prepared in phosphate-buffered saline (PBS) (pH 7.4) for the assay of hepatic TBARs, NADPH-oxidase, and HO-1. Other frozen liver samples were homogenized in RIPA buffer for Western blotting (n = 4/group).

2.3. Biochemical determinations {#sec0025}
-------------------------------

Hepatic thiobarbituric reactive species (TBARs) were assessed spectrophotometrically according to manufacturer instructions (Cayman Chemical, Ann Arbor, MI) as a marker of oxidative stress. NADPH-oxidase activity was measured by lucigenin chemiluminescence (5 μmol/L) in the presence of 100 μmol/L NADPH as previously described ([@bib0160]). Briefly, the liver was homogenized in ice-cold buffer in the presence of protease inhibitors (Phenylmethylsulphonylfluoride 1 mM, Benzamidine-HCl 1 mM, Leupeptin, 0.5 μg/ml, Aprotinin 0.5 μg/ml, Pepstatin 1 mg/ml, NaF 50 mM). 50 μL of homogenate or buffer control was added to the wells of a 96-well micro-plate (OptiPlate-96, Perkin-Elmer, Waltham, MA) and incubated at 37 °C for 30 minutes in the presence of lucigenin (5 μmol/L) and NADPH, and total count per minute (cpm) was normalized to mg protein. Hepatic HO-1 activity, a marker of antioxidant pathway, was measured in liver samples using a commercially available ELISA according to manufacturer\'s instructions (Enzo Life Sciences Inc., Farmingdale, NY).

2.4. Homogenization of the liver for protein expression using Western blotting {#sec0030}
------------------------------------------------------------------------------

Liver samples were homogenized in RIPA buffer in the presence of protease inhibitors. Protein concentrations were determined by standard Bradford assay (Bio-Rad, Hercules, CA) using bovine serum albumin as the standard and liver homogenates were used to determine protein expression levels of hepatic P67, gp91 phox, HIF-1α, P-MAPK, COX-2, and cleaved caspase-9 using Western blotting. Thirty-fifty micrograms of liver samples was separated by SDS-PAGE then transferred onto PVDF membrane. Membranes were blocked in 5% milk in TBS and were incubated with primary antibodies overnight. The blots were then washed in TBS-0.1% Tween and incubated with the secondary antibody goat anti-rabbit or goat anti-mouse (1:5000) conjugated to horseradish peroxidase for 1 hour. Detection was accomplished using enhanced chemiluminescence. Band intensity was measured densitometrically and the values were normalized to β-actin (Sigma, St Louis, MO) using NIH Image J software.

2.5. TUNEL assay {#sec0035}
----------------

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay was used for *in situ* detection of apoptotic cells with a commercially available TUNEL kit (Promega, Madison, USA). Propidium iodide (PI) 1 μg/ml was added as a nuclear counter stain. The number of TUNEL-positive hepatic cells was counted and average TUNEL positive cells per cross sectional area were recorded.

2.6. Statistical analyses {#sec0040}
-------------------------

All data are presented as mean ± SEM and analyzed using one-way ANOVA followed by Tukey\'s post hoc test for multiple group comparisons. Analyses were performed using GraphPad Prism Version 4.0 software (GraphPad Software Inc., La Jolla, CA). For all comparisons, P \< 0.05 was considered statistically significant.

3. Results {#sec0045}
==========

We have previously shown protective effects for DHA against VPA-induced hepatotoxicity. However, the molecular basis of such effects remains unclear. Accordingly, the current study was designed to assess the roles of oxidative stress, inflammation and apoptosis in VPA-evoked liver toxicity and their possible alleviation by DHA.

Because oxidative stress plays a role in the pathogenesis of liver injury, we first assessed whether VPA could elevate oxidative stress in the rat liver. Accordingly, we measured hepatic TBARs levels as a marker of lipid peroxidation. [Fig. 1](#fig0005){ref-type="fig"}A and [Table 1](#tbl0005){ref-type="table"} show that hepatic TBARs levels were significantly elevated in VPA-treated animals and concurrent administration of DHA abated such VPA-evoked lipid peroxidation (P \< 0.05). Besides, the increase in lipid peroxidation was associated with activation of NADPH oxidase, the main source of reactive-oxygen species in the vasculature, in VPA treated rats ([Fig. 1](#fig0005){ref-type="fig"}B and [Table 1](#tbl0005){ref-type="table"}). Moreover, VPA up-regulated expressional levels of the membrane-bound NADPH oxidase catalytic subunit GP91 phox (NOX2) as well as cytoplasmic P67 subunit versus control ([Fig. 1](#fig0005){ref-type="fig"}C,D). Combined administration of DHA reduced VPA-induced NADPH oxidase activation and up-regulation of its subunits. To further gain acumens into the hepatic nuclear changes occurring in VPA-treated rats due to the elevation in oxidative stress, we assessed protein expression levels of HIF-1α and subsequent activation of downstream HO-1 enzyme in the liver ([Fig. 2](#fig0010){ref-type="fig"} and [Table 1](#tbl0005){ref-type="table"}). We also detected a concurrent upregulation of Nrf-2, an upstream factor from HO-1 (data not shown). The elevation in oxidative stress in the livers of VPA-treated rats was associated with upregulation of HIF-1α, an important modulator of transcription in cellular response to variations in systemic oxygen, which displays a multifaceted modulating potential in the mammalian liver ([Fig. 2](#fig0010){ref-type="fig"}A and [Table 1](#tbl0005){ref-type="table"}). Likewise, overexpression of HIF-1α was accompanied by an increase in the hepatic redox-sensitive antioxidant HO-1 level ([Fig. 2](#fig0010){ref-type="fig"}B and [Table 1](#tbl0005){ref-type="table"}). Interestingly, DHA treatment reduced the elevation in expression of hepatic HIF-1α and HO-1 level in VPA-treated rats ([Fig. 2](#fig0010){ref-type="fig"}).

Inflammation plays a crucial role in the pathogenesis of hepatic injury. Thus, we presently assessed the impact of VPA on phosphorylation/activation of MAPK and subsequent downstream inflammatory enzymes, such as COX-2 in rat liver. As shown in [Fig. 3](#fig0015){ref-type="fig"}, VPA increased hepatic phosphorylation of MAPK ([Fig. 3](#fig0015){ref-type="fig"}A) and induced the expression of its downstream inflammatory enzyme COX-2 ([Fig. 3](#fig0015){ref-type="fig"}B and [Table 1](#tbl0005){ref-type="table"}) and these changes were reduced following concurrent administration of DHA.

Furthermore, to determine whether apoptosis is involved in VPA-induced hepatotoxicity, we assessed the DNA-fragmentation, a terminal response in (apopto**t**ic cells) in rat liver using TUNEL assay, and further determined the expressional levels of the pro-apoptotic cleaved caspase-9, in the presence and absence of DHA. VPA caused a significant increase in TUNEL positive cells ([Fig. 4](#fig0020){ref-type="fig"}A), while also increased cleaved caspase-9 expression levels. Both responses to VPA were significantly reduced with DHA administration ([Fig. 4](#fig0020){ref-type="fig"}B).

It is noteworthy to mention that we also treated a rat group with *DHA alone*; however, all results with DHA group were not different from those of control group, thus these data were not presented.

4. Discussion {#sec0050}
=============

We previously demonstrated that DHA can ameliorate VPA-induced hepatotoxicity; however, the underlying molecular mechanisms remain to be delineated. This study targeted the role of key molecular regulators of VPA-induced hepatotoxicity, and further sought the capacity of DHA to counterbalance such signals. Our findings demonstrate that VPA up-regulates NADPH oxidase, ERK1/2 and HIF-1α, as upstream triggers of oxidative stress, hypoxia, inflammation and apoptosis, thereby concluding its profound liver injury. Besides, DHA counteracted VPA-induced hepatotoxicity, by showing anti-oxidant, anti-inflammatory and anti-apoptotic effects. The anti-oxidant/protective profiles of DHA have been demonstrated in human neutrophils and retina ([@bib0125]).

Valproic acid (VPA) is widely prescribed for children with newly diagnosed epilepsy; however, it can induce marked hepatotoxicity which could progress to fatal idiosyncratic reactions ([@bib0060]). VPA-mediated hepatotoxicity is characterized by steatosis, necrosis, depletion of endogenous antioxidants, and disruption of mitochondrial membranes ([@bib0185]).

HIF-1α is a transcription factor that plays a crucial role in cellular response to alterations in systemic oxygen levels in mammals. Accordingly, HIF-1α regulates transactivation of over 60 genes, such as VEGF and erythropoietin, which assist in promoting oxygen delivery to hypoxic regions. VPA modulates HIF-1α expression in diverse tissues, yet in an equivocal directions. In all cases, however, these effects were entailed to the known activity of VPA as a Histone deacetylase (HDAC) inhibitor ([@bib0145]). Thus, HIF-1α repression by VPA was established in human renal cancer cells and in rat gut mucosa. Conversely, in a rat brain stroke model, VPA up-regulated HIF-1α and its downstream proangiogenic factor, vascular endothelial growth factor (VEGF), (HO-1), thereby enhancing angiogenesis and functional recovery from ischemia ([@bib0200]). In the liver, HIF-1α status has never been verified in response to VPA treatment. Currently, we showed up-regulation of HIF-1α following VPA treatment. In the liver, HIF-1α is reportedly induced to aide steatosis, apoptosis and inflammatory/necrotic reactions in response to drug-induced toxicity or environmental insults ([@bib0035]; [@bib0195]; [@bib0230]). Sagaciously, because VPA presently evoked similar hepatic insults, while also induced HIF-1α, similar causalities and implications are warranted. Interestingly, however, we also found that HO-1, a downstream antioxidant signal to HIF-1α, was jointly activated, presumably to oppose/counterbalance oxidative stress. Thus, together, these observations imply that HIF-1α currently stands as a multifaceted modulator of liver cell integrity and viability in response to VPA treatment. With the recent mounting interest in defining therapeutic utility to HIF-1α for an array of liver anomalies ([@bib0205]), further specific/detailed investigations are required to delineate the exact scenario whereby HIF-1α modulates VPA-induced liver injury.

We reported that VPA upregulated inflammatory mediators such as COX-2 in the current study. Furthermore, VPA augmented the abundance of hepatic TUNEL positive cell and cleaved caspase-9 expression, indicating induction of apoptosis *via* hepatic mitochondrial dysfunction. In gastric cancer cell line, the VPA-induced apoptosis was ascribed to acetylation of histone and tubulin ([@bib0215]).

The MAPK (ERK) pathway can play a role in cell growth and survival, or alternatively stimulates inflammatory cascades. In the CNS, the ERK pathway is recruited by neurotrophic factors to maintain neuronal growth, differentiation and survival in the hippocampus and frontal cortex. This pathway, when disrupted, can be restored by drugs intended in mood stabilization, depressive mania and bipolar disorders, like valproate ([@bib0040]; [@bib0055]). In support, chronic treatment of rats with valproate promoted levels of MAPK in relevant neurons ([@bib0075]). Likewise, MAPK ablation disrupted animal behavior and evoked excitements similar to those by psychostimulants such as amphetamine. These responses to ERK ablation were reversed by VPA and olanzapine, thereby substantiating the role of ERK signaling as a target in inducing behavioral anomalies, and for their alleviation by anti-manic drugs ([@bib0055]). Notably as well, HDAC inhibitors were ineffective on such VPA neuronal responses, implying that VPA can undertake multifaceted triggers to activate the neuronal ERK cascade ([@bib0075]). In contrast to the CNS, a paucity of information has been available to link VPA with ERK-activity in the liver. Thus, by far, only one *in vitro* study reported that VPA activates ERK phosphorylation in primary human hepatocytes, a response that was mimicked by HDAC inhibitor, trichostatin-A ([@bib0020]), implying that HDAC inhibition is a primary stimulus for ERK in human hepatocytes. However, this this study has not looked at role of oxidative stress or VPA metabolites, possibly due to limited biologic windows within a cell culture setup.

Currently, in the liver, and following a 2 week of VPA treatment, ERK is up-regulated, yet appears to play a pathogenic role culminating into liver injury. We show here for the first time that VPA up-regulates NADPH oxidase (NOX), as a prime generator of ROS and contributor to oxidative stress. Notably, NOX, in the liver, has been shown as a crucial mediator of diverse deleterious reactions, including inflammation, mitogenesis, fibrosis, apoptosis and steatosis ([@bib0115]; [@bib0140]). In such latter redox-sensitive anomalies, both ERK and NOX appear inevitably involved so as to shape responses to toxins, infections, or malignancies ([@bib0030]). Not surprisingly, cross talk activation between NADPH-oxidase (ROS) and ERK signaling was evident to further recruit additional factors including HIF-1α, as typically shown in mammary cancer cells ([@bib0140]). Our current results indicate a similar hepatic scenario among the three latter effectors, and further implicate COX-2 as an inflammatory co-player, in response to VPA treatment. Congruent to our latest liver finding with VPA, the association between ERK and COX-2 was revealed with other stimuli like phorbol-esters and cytokines in mammary cancer cells and murine auditory cells ([@bib0080]; [@bib0090]).

VPA is a risk factor for developing serious liver injury in patients with Alpers-Huttenlocher syndrome (AHS), a neuro-metabolic disorder that can develop into fatal hepatotoxicity in stressful conditions. Thus, with VPA, this erupts due to disruption of liver cells, which involves a caspase-9-mediated apoptosis ([@bib0120]). It is noteworthy that we have earlier demonstrated, via histopathologic analyses, that apoptosis occurs in the rat liver after similar VPA treatments ([@bib0005]). Therefore, our present study, sought the impact of VPA on expression of cleaved caspase-9 in normal liver in absence of other stressful risk factors, and further attempted to confirm this by an end-point checker for DNA fragmentation, using the TUNEL assay. Thus, VPA markedly augmented cleaved caspase-9 levels to induce apoptosis, as confirmed by the risen abundance of TUNEL-positive hepatocytes. This has been shown to VPA in other non-hepatic tissues, especially cancer cells, and in neural tissues in neonate-animals ([@bib0220]). The present apoptotic reactions were sensitive to DHA treatment, which is consistent with previous observations that DHA supplementation reduces apoptosis in livers from high fat-fed animals ([@bib0175]) and necrosis in response to the cytokine TNF-α ([@bib0150]).

Caspase-9 has repeatedly been shown as a downstream apoptotic trigger from upstream stimuli like NOX/ROS, ERK1/2 or COX-2 ([@bib0225]). These notions prompted us to check for the status of caspase-9, especially where the activation of the aforementioned effectors has presently occurred with VPA treatment. Thus, caspase-9 upregulation was evident with VPA, and further reinforced with TUNEL-assay of hepatocytes. Accordingly, multiple cellular pathways and molecular effectors accumulate, likely in an inter-dependent fashion, to orchestrate hepatic injury in response to VPA. With no rival in seen, hepatic oxidative stress stands as a likely initiator and coordinator of such events. Not surprisingly, strong antioxidants or their combinations have demonstrated considerable efficacy against VPA-evoked liver injury ([@bib0015]; [@bib0025]). Currently, DHA was a superb antioxidant in the rat liver. However, beyond that, omega-3 fatty-acids displayed an array of favorable molecular responses including suppression of prostaglandin formation, and activation of peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptor superfamily of ligand-dependent transcription factors, which suppress cytokine-mediated inflammation. This was documented in cell culture setups by using inhibitors of PPAR-gamma, which abolished the anti-inflammatory response to DHA and EPA fatty acids ([@bib0110]). DHA provides anti-inflammatory effect by favoring the formation of anti-inflammatory prostaglandin E3, at the expense of inflammatory prostaglandin E2. Prostaglandin E3 also inhibits the synthesis of TNF-α and IL-1β ([@bib0130]). Furthermore, Chen and colleagues also showed that DHA down-regulated MAPK, thereby alleviating rodent cholestatic liver injury ([@bib0135]), a consistent observation with our current results which, altogether, substantiate an inflammatory role for ERK in liver cells in response to insults of diverse origin.

5. Conclusion {#sec0055}
-------------

VPA stimulation of molecular triggers of oxidative stress and inflammation such as NADPH oxidase, ERK and HIF-1α exacerbates hepatic injury. The generated oxidative stress, hypoxia and inflammation orchestrate further up-regulation of COX-2 and caspase-9, thereby accentuating hepatocellular apoptosis. HIF-1α apparently assumes a dual role in response to VPA that is not only deleterious. Thus, HIF-1α stimulation of HO-1 as a downstream antioxidant enzyme is only seemingly to lessen the severity of oxidative stress, as implied by the overall cellular outcomes. DHA appreciably abated all of the VPA-evoked liver injury and blunted its evoked hepatocellular apoptosis as well. The fact that DHA possesses anticonvulsant effects ([@bib0050]), and is also able to mitigate liver adverse reactions to VPA, could suggest a powerful drug-combination regimen in the future management of epilepsy.
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Supplementary Material

![Hepatic TBARs levels (A. NADPH oxidase activity (B), and P67 and gp91 (NOX2) expression levels relative to β-actin (C&D) in control and valproate (VPA)-treated rats (500 mg/kg PO, daily) with or without DHA (VPA. 500 mg/kg PO, daily) for two weeks. VPA increased hepatic TBARs levels, activated NADPH oxidase and up-regulated expression levels of NADPH oxidase subunits P67 and gp91 phox when compared to control. Co-administration of DHA prevented VPA-induced oxidative stress. (\*P \< 0.05 vs. control. \#P \< 0.05 vs. VPA-treated rats, n = 6--8/group for TBARs and NADPH oxidase and n = 4 for Western blotting data). Please see Figs. 1S--4S in the Supplementary Material for full blot images 2016.](gr1){#fig0005}

![Hepatic HIF-1α expression relative to β-actin (A), hemeoxygenase-1 (HO-1) levels (B) in control and VPA-treated rats with or without DHA daily treatment for two weeks. HIF-1α levels and HO-1 activity were enhanced in VPA-treated versus control rats, in a DHA-sensitive manner (\*P \< 0.05 vs. control and \#P \< 0.05 vs. VPA-treated rats, n = 6--8/group for HO-1 and n = 4/group for HIF-1α Western blotting). Please see Figs. 5S--6S in the Supplementary Material for full blot images.](gr2){#fig0010}

![Hepatic P-MAPK relative to MAPK (A) and hepatic COX-2 expression levels relative to β-actin (B) in livers of VPA-treated rats +/− DHA. DHA treatment diminished the VPA-induced inflammation (\*P \< 0.05 vs. control and \#P \< 0.05 vs. VPA-treated rats, n = 4/group). Please see Figs. 7S--10S in the Supplementary Material for full blot images.](gr3){#fig0015}

![Representative images (200X) of liver sections for TUNEL assay for detection of apoptotic cells in the presence of Propidium Iodide (PI) as a nuclear counter stain (A), and hepatic cleaved caspase-9 relative to β-actin as a marker of apoptosis (B) in the liver of control and VPA-treated rats with or without DHA supplementation. DHA significantly reduced number of apoptotic cells and attenuated the elevation in cleaved caspase-9 expression shown with VPA-treated rats (\*P \< 0.05 vs. control, n = 4/group). Please see Figs. 11S--12S in the Supplementary Material for full blot images.](gr4){#fig0020}

###### 

Detailed raw data for biochemical assessment of NADPH oxidase, TBARs and HO-1 levels as well as Western blotting densitometric analysis for HIF-1α and COX-2 in control, VPA and VPA plus DHA treated rats.

Table 1

  ----------------------------------------------------------------------------------
                                     **Control**   **VPA**          **VPA + DHA**
  ---------------------------------- ------------- ---------------- ----------------
  **Hepatic TBARs**\                 0.8 ± 0.02    1.1 ± 0.06 \*    0.9 ± 0.08
  (nmol/mg protein)                                                 

  **Hepatic NADPH oxidase**\         26.0 ±0.80    33.0 ± 0.60 \*   27.0 ± 1.20 \#
  (OD/mg protein)                                                   

  **Hepatic HIF-1α**                 1.4 ± 0.07    2.0 ± 0.04 \*    1.5 ± 0.08 \#

  **Hepatic HO-1** (ng/mg protein)   0.98 ± 0.07   1.2 ± 0.05 \*    0.9 ± 0.05 \#

  **Hepatic COX-2** (DU)             0.7 ± 0.06    1.0 ± 0.07 \*    0.74 ± 0.06
  ----------------------------------------------------------------------------------

Data are expressed as means ± SE of the mean. (\*P \< 0.05 vs. control and \#P \< 0.05 vs. VPA-treated rats, n = 4/group for Western blotting and n = 6 for hepatic TBARs and NADPH-oxidase).
